

Vaccination Effectiveness against the Omicron COVID-19 Variant


Brynn Brady

Background: The Omicron Variant

- COVID-19 omicron (B.1.1.529) variant
- First appeared in November 2021 in Botswana and South Africa
- Large concerns arose due to the severe acute respiratory syndromes in vaccinated populations
- Scientists and the community began questioning the vaccines' effectivenesses against the omicron variant, which led to initial molecular biology research on the variant

Initial Molecular and Structural Research

- In comparison to the delta variant, there were significantly more mutations in the omicron from the original virus
- Alarming number of mutations in receptor-binding domains in the spike protein (shown in the pictures to the right)
- These mutations have been associated with increased transmissibility and immune evasion
- We have a reduced neutralizing antibody response to omicron compared to delta
 - Neutralizing antibodies are important for protection against reinfection and initial vaccine effectiveness against infection
- Initial research suggests omicron will be more contagious



Research Question: How does one's vaccination status affect their response to the COVID-19 omicron variant?

My hypothesis:


- Being boosted (3 shots) provides the most protection against severe and mild illness due to omicron
- Being fully vaccinated (2 shots) provides some protection, but this protection has likely waned since one's initial immunization
- No vaccination can provide as much protection against omicron as the other variants

Previous study: Vaccine effectiveness against symptomatic illness from delta and omicron variants


- Observational study conducted earlier this year (April 2022)
- Test-negative case-control design
- Vaccines provide more and longer protection against delta than omicron
- Primary immunization (2 shots) provides no protection against omicron
- Boosters provide substantial and rapid protection against omicron
- Protection from vaccine (primary vaccination or booster) wanes substantially against omicron compared to delta

Critical Findings

B Two Doses of BNT162b2 with a Booster Dose of BNT162b2 or mRNA-1273



C Two Doses of mRNA-1273 with a Booster Dose of BNT162b2 or mRNA-1273



Conclusion: vaccine is more effective and has longer protection against delta than omicron

Figure: Vaccine Effectiveness against Symptomatic Disease Caused by the Delta and Omicron Variants, According to the Period after the Second and Booster Doses

My Methodology

- Survey targeted at the portion of Menlo that has tested positive
- Questions asked:
 - Vaccination status
 - Date of infection (used to determine which variant infected them)
 - Symptom severity (scale from 1, no symptoms, to 4, hospitalization)
 - Symptom length
- Perform basic statistical analysis and chi-squared inference test for independence

Results

		Symptom Length				
		No symptoms	3 days or less	1 or 2 weeks	More than 2 weeks (lingering symptoms)	Total
Vaccination status	Unvaccinated	0	0	3	2	5
	Partially Vaccinated	0	2	1	0	3
	Fully Vaccinated	8	7	7	2	24
	Boosted	5	7	6	3	21
	Total	13	16	17	7	53

		Symptom Severity			
		No symptoms	Light symptoms	Mild Symptoms	Total
Vaccination status	Unvaccinated	0	3	2	5
	Partially Vaccinated	0	2	1	3
	Fully Vaccinated	8	9	7	24
	Boosted	5	9	7	21
	Total	13	23	17	53

Chi-square test for independence shows no statistical significance due to small sample size


Results

Omicron Variant		Non-omicron Variants	
Vaccination Status	Average Symptom Severity	Vaccination Status	Average Symptom Severity
all	2.048	all	2.091
boosted	2.05	boosted	NA
vaccinated	2.053	vaccinated	1.25
unvaccinated	NA	unvaccinated	2.4

Interesting findings about the Menlo community

How severe were your COVID-19 symptoms?


53 responses



- 1 - No symptoms
- 2 - Light (daily activities slightly impaired)
- 3 - Mild (daily activities impaired, no hospitalization)
- 4 - Severe (hospitalization)

What was your vaccination status when you last tested positive for COVID-19?


53 responses



- Unvaccinated
- Partially vaccinated
- Fully vaccinated
- Boosted

What was the length of your COVID-19 symptoms?


53 responses



- No symptoms
- 3 days or less
- A week or less
- 2 weeks or less
- Longer than 2 weeks or lingering symptoms

When did you last test positive for COVID-19?

53 responses



- March 2020 - June 2020
- July 2020 - October 2020
- November 2020 - February 2021
- March 2021 - June 2021
- July 2021 - October 2021
- November 2021 - current day

Conclusion

- Boosters are critical to protection against symptomatic disease from omicron (2 shots provides almost no protection)
- Vaccine effectiveness wanes dramatically more with omicron than other variants
- Did not gather a large enough sample size to find convincing statistical evidence for the importance of vaccination
- Target population in the study is the Menlo community, a highly vaccinated community, and thus, the impact of omicron on unvaccinated individuals could not be studied with much statistical power

Sources

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O'Connell, A., Simons, D., Blomquist, P., Zaidi, A., Nash, S., Aziz, N. I. B. A., Thelwall, S., Dabrera, G., Myers, R., Amirthalingam, G., Gharbia, S., Barrett, J. C., Elson, R., Ladhani, S. N., Ferguson, N., Zambon, M., Campbell, C. N. J., Brown, K., Hopkins, S., Chand, M., Ramsay, M., Bernal, J. L. (2022). Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med* 386, 1532-1546.

Image: <https://cen.acs.org/pharmaceuticals/vaccines/Omicron-puts-scientists-red-alert/99/i44>